Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Science › SpaceX, Tesla Boards Study Possible $3.5 Trillion Merger
Science

SpaceX, Tesla Boards Study Possible $3.5 Trillion Merger

Bloomberg Technology Wednesday 21 October 2026, 16:26 UTC 1 min read
Key Points

Oct 21st, 2026 SpaceX, Tesla Boards Study Possible $3.5 Trillion Merger Elon Musk openly endorsed the prospect of combining SpaceX with Tesla Inc. in what would be the biggest-ever corporate merger, uniting assets from electric cars to AI data centers to rocket and satellite capabilities. Bloomberg's Sana Pashankar joined Bloomberg Intelligence to discuss this as well as SpaceX's recent earnings.

Oct 21st, 2026 SpaceX, Tesla Boards Study Possible $3.5 Trillion Merger Elon Musk openly endorsed the prospect of combining SpaceX with Tesla Inc. in what would be the biggest-ever corporate merger, uniting assets from electric cars to AI data centers to rocket and satellite capabilities. Bloomberg's Sana Pashankar joined Bloomberg Intelligence to discuss this as well as SpaceX's recent earnings.
SpaceX (ORG) Tesla Boards Study Possible (ORG) Elon Musk (PERSON) Tesla Inc. (ORG) AI (ORG) Bloomberg (ORG) Sana Pashankar (PERSON) Bloomberg Intelligence (ORG)
Originally published by Bloomberg Technology Read original →

Related Stories

Controversial US-backed vaccine trial in African newborns halted

Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It is “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”

The Guardian UK 21m ago

Controversial US-backed vaccine trial in African newborns halted

Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It is “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”

The Guardian World 21m ago

Controversial US-backed vaccine trial in African newborns halted

Hepatitis B study in Guinea-Bissau that was to be funded by CDC and that drew global backlash ‘will not move forward’The US-backed hepatitis B vaccine trial in African newborns that drew global backlash was halted, the lead researcher said on Wednesday. It is “now clear” that the study “will not move forward in Guinea-Bissau”, Frederik Schaltz-Buchholzer, a Danish researcher, wrote on LinkedIn, adding, “we were not given the necessary governmental approval.”

The Guardian Health 21m ago

Man with a PhD and Nobel-cited research has sent out 2,300 applications yet cannot land a job

Man with a PhD and Nobel-cited research has sent out 2,300 applications yet cannot land a job Despite unemployment hovering between 3.5 percent and 4.3 percent over the past three years, applicants say finding work remains difficult - Bookmark - CommentsGo to comments Become an Independent member to bookmark this article Already a member? Log in A Princeton University graduate, whose research was cited by the Nobel committee, says he has applied for more than 2,300 jobs since earning his...

The Independent World 24m ago